Capio Biosciences develops the CapioCyte platform, an ultra-sensitive technology for capturing and analyzing circulating tumor cells (CTCs) from whole blood. This platform addresses the limitations of existing CTC capture technologies by providing sensitivity that is 10 to 100 times greater, enabling more informed cancer treatment decisions.
Funding
$2.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Existing circulating tumor cell (CTC) capture technologies lack the sensitivity needed to fully leverage CTCs as biomarkers for informing cancer treatment decisions. This limitation hinders the ability to detect and analyze CTCs effectively, potentially leading to suboptimal treatment strategies.
Solution
Capio Biosciences offers the CapioCyte platform, a technology designed for capturing and analyzing circulating tumor cells (CTCs) from whole blood with enhanced sensitivity. The CapioCyte platform aims to overcome the limitations of current CTC capture methods by achieving a sensitivity level that is 10 to 100 times greater than other available platforms. This improved sensitivity allows for more effective cancer research and has potential clinical applications in the future, enabling oncologists to make more informed treatment decisions.
Target Audience
The primary audience includes oncologists and cancer researchers seeking more sensitive and reliable methods for capturing and analyzing CTCs to improve cancer treatment decisions and research outcomes.
Features
- Ultra-sensitive capture of circulating tumor cells (CTCs) from whole blood.
- Demonstrated sensitivity 10 to 100 times greater than existing CTC capture platforms based on clinical data.